Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
Authors:
- Donald A. BerryDBDonald A. Berry
- Constance CirrincioneCCConstance Cirrincione
- I. Craig HendersonIHI. Craig Henderson
- Marc L. CitronMCMarc L. Citron
- Daniel R. BudmanDBDaniel R. Budman
- Lori J. GoldsteinLGLori J. Goldstein
- Silvana MartinoSMSilvana Martino
- Edith A. PerezEPEdith A. Perez
- Hyman B. MussHMHyman B. Muss
- Larry NortonLNLarry Norton
- Clifford HudisCHClifford Hudis
- Eric P. WinerEWEric P. Winer
Top Cited Papers
Open Access
- 12 April 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (14) , 1658-1667
Abstract
Great strides have been made in the treatment of early stage breast cancer. In patients with hormone-sensitive tumors, tamoxifen reduces the risk of recurrence and death by more than 30%.1 Moreover, treatment with aromatase inhibitors in place of or sequentially with tamoxifen further reduces the risk of recurrence in postmenopausal women with estrogen-receptor (ER)–positive tumors.2-4Keywords
This publication has 30 references indexed in Scilit:
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast CancerJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Comparison of the dose-response relationships of 2 lipid-lowering agents: A Bayesian meta-analysisAmerican Heart Journal, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988